APP下载

探讨低分子肝素治疗慢性阻塞性肺疾病急性加重期的临床治疗效果

2018-01-31赵宏儒

中国实用医药 2018年3期
关键词:急性加重期慢性阻塞性肺疾病

赵宏儒

【摘要】 目的 對慢性阻塞性肺疾病急性加重期患者采取低分子肝素进行治疗, 分析其临床疗效。方法 86例慢性阻塞性肺疾病急性加重期患者, 按照随机原则分为对照组与研究组, 每组43例。对照组进行常规治疗, 研究组在常规治疗的基础上加以低分子肝素进行治疗, 比较分析两组疗效。结果 治疗前, 研究组全血粘度、血浆粘度、纤维蛋白原水平分别为(5.12±0.23)mPa·s、(1.65±0.18)mPa·s、

(5.89±0.89)g/L, 对照组全血粘度、血浆粘度、纤维蛋白原水平分别为(5.15±0.23)mPa·s、(1.63±0.14)mPa·s、

(5.79±0.64)g/L, 比较差异无统计学意义(P>0.05)。治疗后, 研究组全血粘度、血浆粘度、纤维蛋白原水平分别为(3.92±0.16)mPa·s、(0.92±0.18)mPa·s、(3.85±0.23)g/L, 对照组全血粘度、血浆粘度、纤维蛋白原水平分别为(4.25±0.27)mPa·s、(1.15±0.24)mPa·s、(4.34±0.21)g/L, 研究组全血粘度、血浆粘度、纤维蛋白原水平均优于对照组, 差异具有统计学意义(t=6.895、5.027、10.317, P<0.05)。研究组总有效率97.7%高于对照组的83.7%, 差异具有统计学意义(P<0.05)。结论 针对患有慢性阻塞性肺疾病急性加重期患者开展治疗时选用低分子肝素, 能够取得良好的整体疗效, 值得将在临床推广。

【关键词】 低分子肝素;慢性阻塞性肺疾病;急性加重期

DOI:10.14163/j.cnki.11-5547/r.2018.03.046

【Abstract】 Objective To analyze the clinical efficacy of low molecular weight heparin in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods A total of 86 patients with acute exacerbation of chronic obstructive pulmonary disease were randomly divided into control group and research group, with 43 cases in each group. The control group received conventional therapy, and the research group received low molecular weight heparin on the basis of conventional therapy. The efficacy in two groups was compared and analyzed. Results Before treatment, the research group had whole blood viscosity, plasma viscosity and fibrinogen level respectively as (5.12±0.23) mPa·s, (1.65±0.18)mPa·s and (5.89±0.89) g/L, which were respectively (5.15±0.23) mPa·s, (1.63±0.14) mPa·s and (5.79±0.64) g/L in the control group, and their difference was statistically significant (P>0.05). After treatment, the research group had whole blood viscosity, plasma viscosity and fibrinogen level respectively as (3.92±0.16) mPa·s, (0.92±0.18) mPa·s and (3.85±0.23) g/L,

which were respectively as (4.25±0.27) mPa·s, (1.15±0.24) mPa·s and (4.34±0.21) g/L in the control group. The research group had better whole blood viscosity, plasma viscosity and fibrinogen level than the control group, and their difference was statistically significant (t=6.895, 5.027, 10.317, P<0.05). The research group had higher total effective rate as 97.7% than 83.7% in the control group, and the difference was statistically significant (P<0.05). Conclusion For patients with acute exacerbation of chronic obstructive pulmonary disease, application of low molecular weight heparin can achieve good overall efficacy, and this method is worthy of promotion.endprint

【Key words】 Low molecular weight heparin; Chronic obstructive pulmonary disease; Acute exacerbation

慢性阻塞性肺疾病屬于一类常见的呼吸科疾病, 患者在患病后常出现咳嗽、咳痰、喘息等症状, 若疾病处于急性加重期时极易发生心力衰竭、猝死等情况[1-3], 对于患者的生活及生命健康造成极大的不良影响。因此, 在临床治疗中对该疾病的有效治疗十分关注, 尤其是急性加重期, 本研究对患有慢性阻塞性肺疾病急性加重期的患者采取低分子肝素进行治疗取得的临床疗效展开探讨, 现报告如下。

1 资料与方法

1. 1 一般资料 选取2014年4月~2017年2月本院收治的86例慢性阻塞性肺疾病急性加重期患者, 经详细诊断证实为慢性阻塞性肺疾病, 按照随机原则将其分为对照组与研究组, 每组43例。对照……

登录APP查看全文

猜你喜欢

急性加重期慢性阻塞性肺疾病
宽胸理肺汤治疗AECOPD痰浊壅肺证患者30例疗效观察
痰热清雾化治疗慢性阻塞性肺疾病急性加重期的临床效果
无创正压通气联合参麦注射液治疗COPD并呼吸衰竭的临床效果
多元性护理干预对慢性阻塞性肺疾病长期家庭氧疗依从性的应用价值
无创机械通气联合盐酸氨溴索雾化治疗慢性阻塞性肺疾病伴Ⅱ型呼吸衰竭的效果分析
授权理论在使用无创呼吸机COPD患者健康教育中的应用
脾多肽辅助治疗COPD急性加重期患者的临床效果及安全性探讨
无创正压通气治疗慢性阻塞性肺疾病急性加重期合并呼吸衰竭临床研究
莫西沙星治疗慢性阻塞性肺疾病急性加重期疗效和安全性的研究
无创呼吸机治疗AECOPD并发Ⅱ型呼吸衰竭的临床效果